Expert Ratings for Viracta Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Viracta Therapeutics (NASDAQ:VIRX) in the last quarter, with an average price target of $8.4, implying an upside from the current price of $1.31. However, this average has decreased by 52.46% from the previous average price target of $17.67.
August 15, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullish analyst ratings and a higher price target suggest potential upside for Viracta Therapeutics.
Analysts' bullish ratings and a higher price target than the current price indicate a positive outlook for the stock. However, the decrease in the average price target could suggest some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100